Oncology is complex, and traditional diagnostics struggle to keep up. Multiple biomarkers, isolated data, and slow processes delay precision treatments, which means patients might miss the best care and drug developers face challenges in improving clinical trials.
Waiv turns digital pathology and clinical data into AI-powered precision tests that help discover biomarkers and predict outcomes, ready for everyday use. Their products, such as RlapsRisk BC for breast cancer risk, MSIntuit Suite for MSI detection, and BRCAura for gBRCA pre-screening, provide results in minutes through the Destra platform.
Today, Waiv secured $33 million in funding led by OTB Ventures and Alpha Intelligence Capital, with Serena Data Ventures, Karista, and SistaFund also joining.
This investment will help grow their test offerings, deepen pharma R&D partnerships, such as the one with MSD, and expand globally.
Make AI precision testing the global oncology standard via scalable, validated diagnostics
Meriem Sefta, Waiv’s CEO and former Owkin executive, leads the company, which grew out of Owkin’s ten years of medical AI research. Waiv also benefits from the PortrAIt consortium, Europe’s largest multi-institutional precision medicine dataset.
Waiv provides a complete AI system with proprietary models and multimodal analysis of GoldenSite™-style histopathology data. Its main strengths are clinical validation, lab compatibility through Destra, and reliable performance across different regions and labs.
The platform offers useful biological insights from H&E slides, such as gBRCA and MSI detection, all without requiring NGS.
While Tempus and Guardant zero in on genomics, and PathAI or Sopra Steria stick to pathology, Waiv brings it all together: data, validated tests, and workflows, making it easy for pharma and clinicians to collaborate at scale.
What’s next?
Waiv aims to expand its clinical testing portfolio, build stronger pharma partnerships for biomarker discovery and trial support, and broaden access to labs worldwide.
They will also push the PortrAIt consortium to improve dataset diversity and plan to deploy their interoperable platform globally, making AI diagnostics a key part of oncology care.
